While biotech increasingly adopts AI for R&D, manufacturing bottlenecks constrain health innovation. AI and robotics have the ...

WASHINGTON — A broad tariff on imported pharmaceuticals took effect at the end of September, and some biopharma companies and ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks ...

Caribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.

Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug ...

I may have beaten this subject to death over the last month or so, but I cannot resist, and will write about it again.However ...

Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on ...

Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ ...

Biotech and pharma organizations are adopting AI at rapid pace, focusing on R&D, and precision medicine. As challenges emerge ...

Oct 9 (Reuters) - City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market ...